<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5748">
  <stage>Registered</stage>
  <submitdate>10/08/2015</submitdate>
  <approvaldate>10/08/2015</approvaldate>
  <nctid>NCT02521376</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function</studytitle>
    <scientifictitle>A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2016-003266-98</secondaryid>
    <secondaryid>GS-US-339-1631</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Oncology</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Entospletinib

Experimental: Cohort 1 (Moderate Hepatic Impairment) - Entospletinib administered on Days 1-5.

Experimental: Cohort 2 (Severe Hepatic Impairment) - Entospletinib administered on Days 1-5.

Experimental: Cohort 3 (Mild Hepatic Impairment) - Entospletinib administered on Days 1-5.


Treatment: drugs: Entospletinib
Entospletinib 100 mg tablet administered orally twice daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic Parameter: AUC - AUC is defined as the concentration of drug over time (area under the plasma concentration versus time curve)</outcome>
      <timepoint>Day 1; Day 5</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetic Parameter: Cmax - Cmax is defined as maximum observed concentration of drug in plasma</outcome>
      <timepoint>Day 1; Day 5</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Experiencing Adverse Events</outcome>
      <timepoint>Up to Day 9 plus 30 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Experiencing Laboratory Abnormalities</outcome>
      <timepoint>Up to Day 9 plus 30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Calculated body mass index from 18 to 40 kg/m^2

          -  Not pregnant

          -  Normal electrocardiogram

          -  Participants with impaired liver function must be sufficiently healthy based upon
             medical history and physical examination, vital signs, and screening laboratory
             evaluations.

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Participation in another clinical study (current or within last 30 days)

          -  HIV, hepatitis B virus, or active hepatitis C virus infection

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>16/11/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the pharmacokinetics of Entospletinib
      (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function
      (stratified by smoking status, as appropriate) relative to matched, healthy controls.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02521376</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Gilead Study Team</name>
      <address />
      <phone />
      <fax />
      <email>339-1631Study@gilead.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>